$MANE

CHILDS JOHN W sold $10.7M of MANE (indirect holdings)

CHILDS JOHN W sold 100,000 indirectly-held shares of Veradermics, Inc (MANE) at an average of $107.12 ($106.14–$108.24, $10.71M total) across 3 trades on 2026-08-12.

Original reporting
SEC EDGAR · CHILDS JOHN W
Published Aug 14, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANE
Neutral
medium confidence
Mentioned
$MANE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANENeutralLow
01

Why it matters

A director’s open-market sale of 100,000 shares at about $106.14 to $108.24 is disclosed, but there is no accompanying guidance, deal, or operational update.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing alone is unlikely to drive a durable repricing without additional fundamental news.

03

What to watch

The article does not disclose the insider’s cost basis, tax situation, or whether other insiders are selling, limiting inference from this single transaction.

Relevance 7/10Novelty 3/10Timing: filed 2026-08-14 after-hours; sale executed 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Veradermics, Inc (MANE).

Company-level read

Ticker impact

$MANENeutralMedium confidence
Context

Director CHILDS JOHN W sold $10.71M of MANE shares via an open-market sale on 2026-08-12, with holdings after sale at 194,117 shares.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and limited unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing discloses transaction size, price range, and post-sale holdings, but provides no new company-specific operating or regulatory catalyst.

Market effects

No sector read-through is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • Veradermics, Inc

    Company whose director insider sale is reported on SEC Form 4.

  • CHILDS JOHN W

    Director who sold shares indirectly via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEHighAI 8/10

Why This Hair Restoration Biotech's Shares Are Soaring

Veradermics (NYSE: MANE), a biotech company, saw its shares rise 268% post-IPO. Its lead therapy, VDPHL01, showed positive phase 3 trial results, with 78.8% to 85% of patients reporting hair coverage improvements. The drug targets a $30B market for pattern hair loss. The company has $820M in cash and analysts' average price target is $170.

MedAI 9/10

Veradermics’ stock up on male hair loss trial success

Veradermics' stock rose 6% after its Phase III trial for male hair loss drug VDPHL01 met all endpoints, showing significant hair growth vs. placebo. The drug was well-tolerated, with 78.8% and 85.0% of patients reporting improvement in once-daily and twice-daily arms, respectively. Veradermics aims for FDA approval, potentially becoming the first oral pill for pattern hair loss in 30 years.

$MANEHighAI 8/10

Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment

Veradermics (MANE) shares rose 10% after its oral hair-loss pill, VDPHL01, met all primary and secondary goals in a second Phase 3 trial. The pill increased hair count significantly compared to placebo with no serious cardiac events. The company expects 12-month safety data later this year. Veradermics has sufficient cash to potentially reach a launch, according to management.

$MANEHighAI 8/10

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Veradermics (NYSE:MANE) reported positive results from its Phase III trial for VDPHL01 in male pattern hair loss, meeting all endpoints. The trial showed strong growth with mild to moderate adverse events. The company plans to release extension data from Study 302 later this year and expects results from a female pattern hair loss study in 2027. Veradermics has $820 million in cash and is evaluating regulatory filing strategies.